Table 3.
Short-Term Efficacy of Anlotinib Combined with Chemotherapy
| Short-Term Efficacy | Number of Patients (Percent) |
|---|---|
| Complete response (CR) | 0 (0%) |
| Partial response (PR) | 7 (36.8%) |
| Stable disease (SD) | 11 (57.9%) |
| Progressive disease (PD) | 1 (5.3%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.